Biota Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing oral, small molecule compounds to treat respiratory-related viral infections. The Company�s clinical-stage program is laninamivir octanoate, a long-acting neuraminidase inhibitor (NI). It is also engaged in developing BTA-798, also known as vapendavir, which is in Phase 2 for the treatment of human rhinovirus (HRV) infections in patients with moderate to severe asthma. The Company�s Zanamivir is marketed around the world by GlaxoSmithKline plc as Relenza for the prevention and treatment of Influenza A and B. Its Laninamivir Octanoate is marketed by Daiichi Sankyo as Inavir across Japan for the treatment of influenza A and B in adults and children. The lead product from the Company�s collaboration with Daiichi Sankyo for a new class of inhaled long acting NI�s is LANI, also known as CS-8958, which is marketed in Japan as Inavir for the treatment of influenza A and B infections.